AU746277B2 - Method of increasing bone toughness and stiffness and reducing fractures - Google Patents

Method of increasing bone toughness and stiffness and reducing fractures Download PDF

Info

Publication number
AU746277B2
AU746277B2 AU55750/99A AU5575099A AU746277B2 AU 746277 B2 AU746277 B2 AU 746277B2 AU 55750/99 A AU55750/99 A AU 55750/99A AU 5575099 A AU5575099 A AU 5575099A AU 746277 B2 AU746277 B2 AU 746277B2
Authority
AU
Australia
Prior art keywords
bone
pth
risk
parathyroid hormone
vertebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU55750/99A
Other languages
English (en)
Other versions
AU5575099A (en
Inventor
Janet M. Hock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU746277(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU5575099A publication Critical patent/AU5575099A/en
Application granted granted Critical
Publication of AU746277B2 publication Critical patent/AU746277B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
AU55750/99A 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures Expired AU746277B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US60/097151 1998-08-19
US9974698P 1998-09-10 1998-09-10
US60/099746 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2002300163A Division AU2002300163A1 (en) 1998-08-19 2002-07-18 Method of increasing bone toughness and stiffness and reducing fractures

Publications (2)

Publication Number Publication Date
AU5575099A AU5575099A (en) 2000-03-14
AU746277B2 true AU746277B2 (en) 2002-04-18

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55750/99A Expired AU746277B2 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Country Status (32)

Country Link
US (2) US6977077B1 (OSRAM)
EP (3) EP2266598B1 (OSRAM)
JP (5) JP2002523375A (OSRAM)
KR (1) KR100454207B1 (OSRAM)
CN (1) CN1205997C (OSRAM)
AR (1) AR033639A1 (OSRAM)
AT (1) ATE231000T1 (OSRAM)
AU (1) AU746277B2 (OSRAM)
BR (1) BR9909445A (OSRAM)
CA (1) CA2325371C (OSRAM)
CO (1) CO5130020A1 (OSRAM)
CY (2) CY1113343T1 (OSRAM)
CZ (1) CZ301017B6 (OSRAM)
DE (2) DE15152726T1 (OSRAM)
DK (4) DK1769804T3 (OSRAM)
DZ (1) DZ2873A1 (OSRAM)
EA (1) EA003362B1 (OSRAM)
ES (4) ES2190244T3 (OSRAM)
HR (1) HRP20000755A2 (OSRAM)
HU (2) HU1200430D0 (OSRAM)
ID (1) ID29039A (OSRAM)
IL (2) IL138829A0 (OSRAM)
MY (1) MY129227A (OSRAM)
NO (2) NO323984B1 (OSRAM)
NZ (1) NZ507056A (OSRAM)
PE (1) PE20001089A1 (OSRAM)
PL (1) PL201688B1 (OSRAM)
PT (4) PT1059933E (OSRAM)
TR (1) TR200003455T2 (OSRAM)
TW (1) TW576747B (OSRAM)
UA (1) UA72205C2 (OSRAM)
WO (1) WO2000010596A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
AU2004273660B2 (en) * 2003-09-19 2010-08-19 Wisconsin Alumni Research Foundation (Warf) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
WO2005115441A2 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
CA2566032A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
PL2136850T3 (pl) 2007-04-13 2012-07-31 Kuros Biosurgery Ag Polimeryczny uszczelniacz tkankowy
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
WO2009072119A2 (en) * 2007-12-04 2009-06-11 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
CA2710798A1 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
RU2564894C2 (ru) 2009-09-09 2015-10-10 Асахи Касеи Фарма Корпорейшн Ртн-содержащий терапевтический/профилактический агент против остеопороза, характеризующийся тем, что ртн вводят один раз в неделю в стандартной дозе 100-200 единиц
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
CN103561757B (zh) 2011-06-07 2016-01-06 旭化成制药株式会社 高纯度含pth冷冻干燥制剂及其制造方法
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
EP3875105B1 (en) 2018-10-29 2024-11-27 Asahi Kasei Pharma Corporation An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
JP7684951B2 (ja) 2019-08-09 2025-05-28 フラッグシップ・パイオニアリング・イノベーションズ・ブイアイ，エルエルシー 副甲状腺ホルモン受容体（ｐｔｈｒ１）の調節剤
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
WO1998014478A1 (en) * 1996-09-30 1998-04-09 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU4472896A (en) * 1994-12-19 1996-07-10 Beth Israel Hospital Association, The Continuous low-dose administration of parathyroid hormone or its agonist
JPH10511090A (ja) * 1994-12-22 1998-10-27 アストラ・アクチエボラーグ 副甲状腺ホルモン，ｐｔｈ含有吸入用治療製剤
WO1999012561A2 (en) * 1997-09-09 1999-03-18 F. Hoffman-La Roche Ag FRACTURE HEALING USING PTHrP ANALOGS
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
WO1998014478A1 (en) * 1996-09-30 1998-04-09 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist

Also Published As

Publication number Publication date
TR200003455T2 (tr) 2001-06-21
CN1308545A (zh) 2001-08-15
ES2549551T1 (es) 2015-10-29
AU5575099A (en) 2000-03-14
EP1059933A1 (en) 2000-12-20
ID29039A (id) 2001-07-26
HK1030545A1 (en) 2001-05-11
MY129227A (en) 2007-03-30
HK1102496A1 (en) 2007-11-23
HRP20000755A2 (en) 2001-02-28
IL138829A (en) 2011-01-31
JP2015028065A (ja) 2015-02-12
CO5130020A1 (es) 2002-02-27
ATE231000T1 (de) 2003-02-15
DK2907522T1 (da) 2015-10-19
CZ301017B6 (cs) 2009-10-14
NZ507056A (en) 2003-10-31
KR100454207B1 (ko) 2004-10-26
ES2393200T3 (es) 2012-12-19
CY1113343T1 (el) 2016-06-22
JP2017190332A (ja) 2017-10-19
CA2325371A1 (en) 2000-03-02
ES2621653T3 (es) 2017-07-04
PL343595A1 (en) 2001-08-27
CZ20004134A3 (cs) 2001-08-15
DE15152726T1 (de) 2015-12-10
CN1205997C (zh) 2005-06-15
HK1212602A1 (en) 2016-06-17
PT2907522T (pt) 2017-10-23
BR9909445A (pt) 2000-12-12
EA003362B1 (ru) 2003-04-24
ES2190244T3 (es) 2003-07-16
US20050197294A1 (en) 2005-09-08
DK1059933T3 (da) 2003-04-07
JP2002523375A (ja) 2002-07-30
UA72205C2 (uk) 2005-02-15
JP6177718B2 (ja) 2017-08-09
DK2266598T3 (en) 2017-05-15
JP2011021035A (ja) 2011-02-03
EP2266598A1 (en) 2010-12-29
HUP0101594A3 (en) 2002-01-28
CY1119552T1 (el) 2018-03-07
PT1769804E (pt) 2012-11-13
PL201688B1 (pl) 2009-04-30
NO20072983L (no) 2000-11-24
JP2014139220A (ja) 2014-07-31
KR20010072763A (ko) 2001-07-31
WO2000010596A1 (en) 2000-03-02
EP2907522B1 (en) 2017-08-02
HUP0101594A2 (hu) 2001-11-28
NO20005947L (no) 2000-11-24
HU230697B1 (hu) 2017-09-28
TW576747B (en) 2004-02-21
HU1200430D0 (hu) 2001-11-28
EP2266598B1 (en) 2017-02-22
DK1769804T3 (da) 2012-10-15
ES2549551T3 (es) 2017-11-27
AR033639A1 (es) 2004-01-07
IL138829A0 (en) 2001-10-31
PT2266598T (pt) 2017-05-02
DK2907522T3 (en) 2017-10-23
DE69904918T2 (de) 2003-11-13
CA2325371C (en) 2004-08-17
PE20001089A1 (es) 2000-11-04
US7163684B2 (en) 2007-01-16
US6977077B1 (en) 2005-12-20
NO20005947D0 (no) 2000-11-24
DE69904918D1 (de) 2003-02-20
EA200001015A1 (ru) 2001-02-26
EP1059933B1 (en) 2003-01-15
EP2907522A1 (en) 2015-08-19
DZ2873A1 (fr) 2003-12-15
NO323984B1 (no) 2007-07-30
PT1059933E (pt) 2003-06-30

Similar Documents

Publication Publication Date Title
AU746277B2 (en) Method of increasing bone toughness and stiffness and reducing fractures
US7351414B2 (en) Method of reducing the risk of bone fracture
Mashiba et al. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits
EP1136076A1 (en) Method of increasing bone toughness and stiffness and reducing fractures
EP1769804A2 (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1037333A (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1212602B (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1030545B (en) Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture
HK1102496B (en) Hpth(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
MXPA00009982A (en) Method of increasing bone toughness and stiffness and reducing fractures

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired